Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?

Leukemia. 2013 Sep;27(9):1939-40. doi: 10.1038/leu.2013.112. Epub 2013 Apr 22.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Arterial Occlusive Diseases / complications*
  • Benzamides / adverse effects*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Peripheral Arterial Disease / complications*
  • Piperazines / adverse effects*
  • Pyrimidines / adverse effects*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines